Abstract:The immune system is the hard-wired host defense mechanism against pathogens as well as cancer. Five years ago, we pondered the question if the era of cancer immunotherapy was upon us (Li et al., Exp Hem Oncol 2013). Exciting progresses have been made at all fronts since then, including (1) sweeping approval of six agents by the US Food and Drug Administration (FDA) to block the PD-1/PD-L1 pathway for treatment of 13 cancer types; (2) a paradigm shifting indication of PD-1 and CTLA4 blockers for the management of a broad class of cancers with DNA mismatch repair defect, the first-ever tissue agnostic approval of cancer drugs; (3) real world practice of adoptive T cell therapy with two CD19-directed chimeric antigen receptor T cell products (CAR-T) for relapsed and/or refractory B cell malignancies including acute lymphoid leukemia and diffuse large B cell lymphoma, signaling the birth of a field now known as synthetic immunology; (4) the award of 2018 Nobel Prize in Physiology and Medicine from the Nobel Committee to Tasuku Honjo and James Allison “for their discovery of cancer medicine by inhibition of negative immune regulation” (www.nobelprize.org/prizes/medicine/2018); and (5) the emerging new concept of normalizing rather than amplifying anti-tumor immunity for guiding the next wave of revolution in the field of immuno-oncology (IO) (Sanmamed and Chen, Cell 2018).This article will highlight the significant developments of immune-oncology as of October 2018. The US FDA approved indications of all seven immune checkpoint blockers, and two CD19-directed CAR-T products are tabulated for easy references. We organized our discussion into the following sections: introduction, cell therapy, emerging immunotherapeutic strategies, expediting oncology drug development in an era of breakthrough therapies, new concepts in cancer immunology and immunotherapy, and concluding remarks. Many of these topics were covered by the 2018 China Cancer Immunotherapy Workshop in Beijing, the fourth annual conference co-organized by the Chinese American Hematologist and Oncologist Network (CAHON), China FDA (CFDA; now known as China National Medical Product Administration (NMPA)), and the Tsinghua University. We significantly expanded our discussion of important IO developments beyond what were covered in the conference, and proposed a new Three Rs conceptual framework for cancer immunotherapy, which is to reverse tolerance, rejuvenate the immune system, and restore immune homeostasis. We conclude that the future of immuno-oncology as a distinct discipline of cancer medicine has arrived.

The Era of Immune Checkpoint Therapy: from Cancer to Viral Infection—A Mini Comment on the 2018 Medicine Nobel Prize

[Immune checkpoint inhibitors. A breakthrough in cancer therapy].

New principles of cancer therapy give new hope for oncological patients

Recent Developments in Gene Therapy and Immunotherapy

Cancer Immunotherapy: An Overview on Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021).

The future of immune checkpoint therapy

Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

Cancer Immunotherapy: an Evolving Paradigm

Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy

[Immune-checkpoints: the new anti-cancer immunotherapies]

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.

Strategies to optimize the promise of checkpoint-targeted anti-cancer therapy

Role of miRNAs in immune responses and immunotherapy in cancer

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

Immune Checkpoints in Cancers: From Signaling to the Clinic

The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy

A brand new era of cancer immunotherapy: breakthroughs and challenges

The New Progress in Cancer Immunotherapy

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases

Abstract 2675: A new dual-targeting anti-immune checkpoint therapeutic approach for the treatment of “hot” and “cold” tumors